Drug Information

General Information
Drug ID
DR00301
Drug Name
Doxorubicin
Synonyms
14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; ADM; ADR; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastin; Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin; Adriamycin PFS; Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF; Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriamycin semiquinone; Adriblas tina; Adriblastin; Adriblastina; Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Aerosolized Doxorubicin; Caelyx (TN); Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DM2; DOX-SL; Doxil; Doxorubicin (USAN/INN); Doxorubicin Hydrochloride; Doxorubicin [USAN:INN:BAN]; Doxorubicin citrate; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Doxorubicina; Doxorubicina [INN-Spanish]; Doxorubicine; Doxorubicine [INN-French]; Doxorubicinum; Doxorubicinum [INN-Latin]; FI 106; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); JT9100000; Myocet; Myocet (TN); NDC 38242-874; RDF Rubex; Resmycin; Rubex; Rubex (TN); Rubex (hydrochloride salt); TLC D-99; ThermoDox
Drug Type
Small molecular drug
Indication Leukemia [ICD11: 2A60-2B33] Approved [1]
Hodgkin lymphoma [ICD11: 2B30] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C27H29NO11
Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
InChIKey
AOJJSUZBOXZQNB-TZSSRYMLSA-N
CAS Number
CAS 23214-92-8
Pharmaceutical Properties Molecular Weight 543.5 Topological Polar Surface Area 206
Heavy Atom Count 39 Rotatable Bond Count 5
Hydrogen Bond Donor Count 6 Hydrogen Bond Acceptor Count 12
XLogP
1.3
PubChem CID
31703
PubChem SID
11466466 , 11467586 , 11486131 , 11533222 , 11538021 , 14910387 , 14910388 , 17397983 , 24769891 , 26704333 , 26709766 , 34673809 , 46507641 , 47440542 , 47515588 , 47589229 , 47736754 , 47811027 , 47811028 , 48035406 , 4809 , 48185239 , 48414671 , 48415928 , 49698493 , 49846798 , 49855190 , 50063935 , 53787595 , 53837797 , 56310844 , 56311108 , 56311939 , 56312034 , 56312063 , 56312270 , 56312524 , 56312768 , 56313130 , 56313308 , 56313325 , 56313365 , 56313675 , 56313990 , 56314080 , 56314176 , 596007 , 7887074 , 7979129 , 8172352
ChEBI ID
ChEBI:28748
TTD Drug ID
D07VLY
DT(s) Transporting This Drug ABCB5 Transporter Info ATP-binding cassette sub-family B member 5 Substrate [2]
ABCB8 Transporter Info ATP-binding cassette sub-family B member 8 Substrate [3]
BCRP Transporter Info Breast cancer resistance protein Substrate [4]
FLIPT2 Transporter Info Fly-like putative transporter 2 Substrate [5]
MCT1 Transporter Info Monocarboxylate transporter 1 Substrate [6]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [7]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [8]
P-GP Transporter Info P-glycoprotein 1 Substrate [9]
P-GP Transporter Info P-glycoprotein 1 Substrate [10]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 5 microM Spodoptera frugiperda (Sf9) cells-BCRP [11]
P-GP Transporter Info Km = 3 microM KB-V1 cells-overexpress MDR1 [12]
References
1 Doxorubicin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
3 ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
4 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
5 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
6 Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
7 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
8 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
9 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
10 Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
11 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
12 Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.